Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105040 · ClinicalTrials.gov registry record · Phase 2
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
A Phase 2 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT00105040 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 87 participants.
The verdict
NCT00105040, a Phase 2 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.
Interventions
- DRUG Levetiracetam
- OTHER Placebo (PB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105040
The ClinicalTrials.gov registry entry for NCT00105040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levetiracetam is the first listed.
NCT00105040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105040 about?
NCT00105040 is a clinical study titled "A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures". A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.
What is the current status of trial NCT00105040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2004-09. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00105040?
The interventions under investigation include: Levetiracetam (DRUG), Placebo (PB) (OTHER).
Who is sponsoring clinical trial NCT00105040?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.